{"id":209088,"date":"2023-01-19T00:20:31","date_gmt":"2023-01-18T18:50:31","guid":{"rendered":"https:\/\/arunachaltimes.in\/?p=209088"},"modified":"2023-01-19T00:20:31","modified_gmt":"2023-01-18T18:50:31","slug":"serum-institute-seeks-inclusion-of-covid-jab-covovax-in-cowin-portal","status":"publish","type":"post","link":"https:\/\/arunachaltimes.in\/index.php\/2023\/01\/19\/serum-institute-seeks-inclusion-of-covid-jab-covovax-in-cowin-portal\/","title":{"rendered":"Serum institute seeks inclusion of Covid Jab &#8216;Covovax&#8217; in CoWIN portal"},"content":{"rendered":"<p style=\"text-align: justify;\">New Delhi, 18 Jan: Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday.<br \/>\nThe letter was written by Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII), they said.<br \/>\nNational Technical Advisory Group on Immunisation (NTAGI) is likely to hold a meeting soon to decide on the matter.<br \/>\nThe Drug Controller General of India (DCGI) on January 16 approved market authorisation for Covovax as a heterologous booster dose for adults who have been administered two doses of either Covishield or Covaxin.<br \/>\nIts approval was based on recommendations by the subject expert committee (SEC) of the Central Drugs Standard Control Organisation.<br \/>\nThe DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and also in children aged seven to 11 years on June 28 last year subject to certain conditions.<br \/>\nCovovax is manufactured through technology transfer from Novavax.<br \/>\nIt has been approved by the European Medicines Agency for conditional marketing authorization and was granted emergency-use listing by the World Health Organization (WHO) on December 17, 2021.<br \/>\nIn August 2020, US-based vaccine maker Novavax Inc. had earlier announced a license agreement with the SII for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in India and low-and-middle-income countries. PTI<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Delhi, 18 Jan: Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday. The letter was written by Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":{"0":"post-209088","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-national"},"_links":{"self":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/posts\/209088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/comments?post=209088"}],"version-history":[{"count":0,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/posts\/209088\/revisions"}],"wp:attachment":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/media?parent=209088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/categories?post=209088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/tags?post=209088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}